Global

Making sense of surprise rejection of draft proposals.

Commercial Health Insurance may bring more opportunities for market access in China.

Global go-to-market strategies in region require a revamped gameplan.

Patient safety and data protection concerns highlight hesitancy.

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

And, in equal measure, patients and doctors—as EU mulls new rules.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Jimenez discusses bringing care to diverse and underserved communities.

Industry leaders discuss new technologies, research, and investment strategies.

Continent has shed its ‘emerging’ status on world biopharma stage.

Legislative-reform alliance makes for strange bedfellows.

Group’s ideas to change EU pricing rules draw captive audience.

Investments setting up sector for future success that could one day rival its US counterpart.

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Recent growth in pharma makes Ireland an ideal candidate for expansion opportunities.

The risky business of outmaneuvering Europe’s drug pricing authorities.

Brexit and the pandemic continue to complicate flow of international talent.

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Exploring the market’s emergence on the global stage.

Fresh round of discussions around health technology assessment.

Efforts for a standardized approach coming to a head in Europe.

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.